Regeneron Pharmaceuticals (REGN) to Release Earnings on Thursday

Regeneron Pharmaceuticals (NASDAQ:REGN) is expected to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $10.21 per share and revenue of $3.8121 billion for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period last year, the company posted $8.22 earnings per share. On average, analysts expect Regeneron Pharmaceuticals to post $37 EPS for the current fiscal year and $42 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $651.18 on Thursday. Regeneron Pharmaceuticals has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The firm’s 50 day simple moving average is $637.84 and its 200-day simple moving average is $715.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The company has a market cap of $68.84 billion, a P/E ratio of 15.87, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on REGN shares. Royal Bank Of Canada cut their target price on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 7th. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research report on Monday, May 18th. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Finally, Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $787.88.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Guggenheim raised its price target on Regeneron to $1,000 from $995 and reiterated a buy rating, signaling continued confidence in the company’s longer-term upside. Benzinga
• Neutral Sentiment: Regeneron also provided an update that its mid-stage POTS study for REGN7544 has wrapped up, but the article does not include enough detail to gauge the readout’s financial or clinical impact yet. TipRanks
• Negative Sentiment: Several firms, including Bronstein, Gewirtz & Grossman, Bernstein Liebhard, Bleichmar Fonti & Auld, Pomerantz, the Schall Law Firm, and others, announced or promoted a class action lawsuit against Regeneron over alleged securities-law violations tied to trial disclosures and the subsequent stock decline, keeping legal risk in focus for investors. PR Newswire

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Dodge & Cox raised its holdings in shares of Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after acquiring an additional 45,513 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Regeneron Pharmaceuticals by 142.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. Invesco Ltd. increased its position in Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock worth $834,675,000 after purchasing an additional 408,649 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 38.0% during the 4th quarter. AQR Capital Management LLC now owns 995,710 shares of the biopharmaceutical company’s stock worth $768,518,000 after purchasing an additional 274,356 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Northern Trust Corp now owns 984,792 shares of the biopharmaceutical company’s stock valued at $553,719,000 after buying an additional 26,223 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.